Invited Lectures in International Meetings

1. Invited speaker, “Identification of anti-virulence compounds for combating Staphylococcus aureus infections by high-throughput screening (HTS)”, at the 4th International Conference on Prevention & Infection Control (ICPIC 2017), June 20-23, 2017 (Geneva, Switzerland).

2. Invited speaker, “Identification and mechanistic study of a novel compound suppressing the expression of multiple virulence genes in Staphylococcus aureus”, at ASM Microbe 2016, June 16-20, 2016 (Boston, USA).

3. Invited speaker, “An induced-fit binding model for nucleozin-mediated influenza A nucleoprotein (NP) aggregation”, at 28th International Conference on Antiviral Research, May 11-15, 2015 (Rome, Italy).

4. Invited speaker, “Identification of new druggable antiviral targets by chemical genetics”, at 24th International Conference on Antiviral Research, May 8-11, 2011 (Sofia, Bulgaria).

5. Invited speaker, “Identification of influenza A nucleoprotein as a new antiviral target by chemical genetics”, at Influenza Congress USA-2010, November 9-10, 2010 (Washington D.C., USA).

6. Invited speaker, “Identification of new antiviral targets by chemical genetics”, at International Conference on Antivirals for Neglected and Emerging Viruses ICAV -9, October 10-13, 2010 (Lubeck, Germany).

7. Keynote speaker, “Identification of new druggable targets in viral infections by chemical genetics”, at World Congress of Virus and Infections-2010, July 31-August 3, 2010 (Busan, Korea).

8. “New targets in influenza A – a chemical genetic approach”, at Xiemen University, September 17-20, 2009 (Xiamen, China).

9. “Chemical genetics: a powerful tool to uncover new druggable targets in pathogens?” at Hong Kong Chemical Biology Symposium 2009, May 25, 2009 (The University of Hong Kong, Hong Kong).

10. “High throughput screening and chemical genetics” at Workshop on Systems Biology 2008, August 18-29, 2008 (City University of Hong Kong).

11. Invited speaker, “New druggable targets, novel anti-flu compounds”, at World Summit of Antivirals-2008, July 20-26, 2008 (Kunming, Yunnan, China).

12. Invited speaker, “New druggable targets, novel anti-flu compounds”, at Frontiers in Biomedical Research, December 13, 2007 (Hong Kong).

13. “Novel antiviral agents and chemical genetics: from SARS-CoV to influenza”, at Hong Kong – British Columbia Workshop On Emerging Infectious Diseases, June 15-16, 2007 (Vancouver, Canada).

14. “Antiviral drug discovery” at HKU - UBC Emerging Infectious Diseases Workshop, December 9-10, 2006 (The University of Hong Kong).

15. Invited speaker, “Identification of novel small molecule compounds that differentially inhibit the yeast form of Penicillium marneffei”, at the 8th International Mycological Congress, August 21-25, 2006 (Cairns, Australia).

16. Invited speaker, “Application of chemical genetics in virology – the SARS-CoV story”, at Drug Discovery Technology World Congress, August 8-11, 2005 (Boston, USA).

17. Invited speaker, “Identification of novel small molecule inhibitors of SARS-CoV by chemical genetics”, at International Consortium of Antivirals, March 8-11, 2005 (Paris, France).

18.  “Novel antiviral agents and chemical genetics: from SARS-CoV to influenza”, at HKU- NTU Symposium on Emerging Infectious Diseases, November 25, 2004 (Taiwan).

19. Invited speaker, “Identification of novel small molecule inhibitors of SARS-CoV by chemical genetics”, at International Drug Discover Science and Technology, November 1-4, 2004 (Beijing, China).

20. Invited speaker, “Fungal ribotoxins: a family of naturally engineered targeted toxins?”, at Swiss Institute of Allergy and Asthma Research., July, 1996 (Davos, Switzerland).

21. Invited speaker, “Site-directed mutagenesis of the mitogillin gene”, at Frontiers in Translation: An International Conference on the Structure and Function of the Ribosome, May, 1995 (Victoria, B.C., Canada).